Loading...

Table of Content

    15 April 2023 Volume 41 Issue 4
      
    Commentary
    Early diagnosis and precise intervention of neonatal hyperammonemia
    ZHANG Yongjun, ZHU Tianwen
    Journal of Clinical Pediatrics. 2023, 41(4):  241-246.  doi:10.12372/jcp.2023.23e0164
    Abstract ( 310 )   HTML ( 40 )   PDF (1156KB) ( 335 )  
    References | Related Articles | Metrics

    Neonatal hyperammonemia (NHA) is a neonatal critical disease with high neonatal mortality and rapid progression. During the neonatal period, increased blood ammonia can be caused by a variety of genetic and non-genetic disorders with complex causes, such as urea cycle disorders, organic acidemia, fatty acid metabolism disorders, and acquired hyperammonemia due to other serious systemic diseases. The presenting clinical features are not specific. Early detection and identification of etiology and precise intervention through feeding management, amino-reducing drug and hemodialysis can improve the prognosis.

    Expert Review
    Attention should be paid to neonatal hyperammonemia
    CHEN Yan, WANG Lin
    Journal of Clinical Pediatrics. 2023, 41(4):  247-251.  doi:10.12372/jcp.2022.22e1743
    Abstract ( 249 )   HTML ( 35 )   PDF (1220KB) ( 154 )  
    Figures and Tables | References | Related Articles | Metrics

    Neonatal hyperammonemia has complex etiology and rapid progression. If missed diagnosis or blood ammonia is not timely controlled, it will lead to life-threatening or poor prognosis of the child. However, due to the lack of specificity of clinical manifestations of neonatal hyperammonemia and the lack of knowledge of the disease, it often leads to misdiagnosis or missed diagnosis. This article summarizes and discusses the clinical problems in the diagnosis and treatment of neonatal hyperammonemia, in order to improve the attention and treatment level of clinicians, and reduce the disability rate and mortality.

    Neonatal Disease
    A multicenter survey and clinical analysis of neonatal hyperammonemia
    Shenzhen Neonatal Data Network
    Journal of Clinical Pediatrics. 2023, 41(4):  252-258.  doi:10.12372/jcp.2023.22e1736
    Abstract ( 303 )   HTML ( 24 )   PDF (1255KB) ( 142 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the incidence, etiological classification, clinical features and prognosis of neonatal hyperammonemia through a retrospective multi-center status survey. Methods Neonatal patients with blood ammonia levels more than 100 μmol/L who were treated in 28 participating units between January 2017 and November 2022 made up the study population. The incidence, etiological classification, clinical traits, genetic phenotype, and prognostic follow-up of neonates with confirmed hyperammonemia were analyzed using descriptive study methodologies. Results During the observation period, the total number of deliveries in 28 units was 708421, and 73 newborns met the diagnostic criteria of neonatal hyperammonemia, including 44 boys and 29 girls. The etiological classification included congenital hyperammonemia (24 cases, 32.88%), transient hyperammonemia (11 cases, 15.07%), secondary hyperammonemia (12 cases, 16.44%), and unexplained hyperammonemia (26 cases, 35.61%). The main clinical manifestations were poor response, shortness of breath, feeding difficulties, convulsions and impaired consciousness. The main abnormal laboratory tests were metabolic acidosis, increased blood lactate, hypoglycemia, electrolyte disorders, abnormal blood and/or urine amino acids. Genetic tests were performed in 13 patients, and abnormalities were found in 11 of them. In addition to conventional symptomatic supportive treatment, arginine intravenous drip (21 cases), carnitine supplementation (8 cases), blood purification (9 cases) and peritoneal dialysis (3 cases) were mainly used. The prognosis for the 24 cases of congenital hereditary hyperammonemia was 10 deaths, 6 treatment discontinuations, and 8 discharges. Among the 12 children with secondary hyperammonemia, 1 died, 3 gave up treatment, 1 had an unknown prognosis, and 7 were cured and discharged from hospital. All 11 cases of temporary hyperammonemia were cured or improved and discharged from hospital. Among 26 cases of unknown hyperammonemia, 17 died, 4 gave up treatment, 3 had unknown prognosis, and 2 were discharged from hospital after improvement. Conclusions Neonatal hyperammonemia is uncommon, but it progresses swiftly and has a high risk of mortality, particularly in cases of congenital genetic hyperammonemia and unexplained hyperammonemia. Raising doctors' awareness of the condition and promoting early detection and treatment can reduce mortality and serious consequences. Moreover, setting up screening and registration procedures for newborn hyperammonemia as well as improving prenatal consultation are helpful for clinical outcomes.

    Genetic screening and early intervention in neonatal hyperammonemia caused by urea cycle disorder
    ZHANG Yinchun, MO Wenhui, BAI Bo, CHEN Jinmian, SHI Congcong, GU Xia, XIAO Xin, HAO Hu
    Journal of Clinical Pediatrics. 2023, 41(4):  259-265.  doi:10.12372/jcp.2023.22e1714
    Abstract ( 271 )   HTML ( 26 )   PDF (1299KB) ( 241 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To explore the prevalence of neonatal urea circulation disorder (UCD) by genetic screening and achieve the early identification and intervention of neonatal hyperammonemia (NHA) caused by UCD in Guangdong province. Methods The gene screening data of 38159 neonates from multiple centers in Guangdong region from 2019 to 2022 were collected, and the gene positive rate of UCD neonates was calculated. Meanwhile, the clinical intervention and efficacy of 9 children with UCD related NHA were further analyzed. Results The gene positive rate of UCD in newborns in Guangdong was 0.472%, and citrin deficiency was the commonest (0.314%). All three cases of citrin deficiency had homozygous variation of c.852_855delTATG in SLC25A13 gene. Due to the different diagnosis time and clinical intervention period, the prognosis of children is also different. Six children with UCD related NHA had early onset and advanced progression. After active early symptomatic treatment, two patients with citrullinemia typeⅠimproved, four patients died and one was lost to follow-up. Conclusions The etiology of NHA is complex and diverse, and UCD is the commonest. Its clinical manifestations lack specificity, and it is easy to be missed and misdiagnosed. Early blood and urine metabolism screening combined with UCD-related gene screening can achieve early identification, diagnosis and treatment of UCD-related NHA, and can guide genetic counseling and prenatal diagnosis of another pregnancy.

    Clinical analysis of urea cycle disorders in 5 neonates
    CHU Xiaoyun, SUN Yifan, YAN Chongbing, HONG Wenchao, GONG Xiaohui, CAI Cheng
    Journal of Clinical Pediatrics. 2023, 41(4):  266-271.  doi:10.12372/jcp.2023.22e1656
    Abstract ( 326 )   HTML ( 25 )   PDF (1215KB) ( 165 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To summarize the clinical features, diagnosis and treatment, regression and prognosis of 5 neonatal urea cycle disorders (UCDs) in order to improve the understanding of the disease. Methods The clinical characteristics, treatment and prognosis of 5 neonatal UCDs confirmed by gene sequencing admitted from July 2017 to July 2022 were retrospectively analyzed. Results The gestational age of the five neonates (4 boys and 1 girl) was (39.0±1.2) weeks, the birth weight was (3642.0±511.6) g, the age of onset was 2(1-5) days, and the initial blood ammonia level was (1386.8±398.4) μmol/L. The onset characteristics of the children were poor appetite (3 cases), hypothermia (2 cases), shortness of breath (2 cases) and vomiting (1 case). All the children had hypotonia, disturbance of consciousness and convulsion. The primary disease was ornithine transcarbamylase deficiency (OTCD) in 3 cases and carbamoyl phosphate synthase 1 deficiency (CPS1D) in 2 cases. Decreased citrulline and increased urinary orotate was found in children with OTCD, and there were three gene pathogenic variants, among which c.177delA and c.387-1G>T were new variants. In CPS1D children, citrulline was decreased, urinary orotate concentration was normal or decreased, and four variation loci were found by gene sequencing, among which c.548T>C and c.3G>C were new variants. All 5 neonates with UCDs were treated with diet control and medication followed by dialysis for rapid clearance of ammonia, and the blood ammonia level in 3 of them decreased to (164.0±47.1) μmol/L. However, due to the poor prognosis of the nervous system, 4 patients died and 1 patient survived. The surviving neonate underwent liver transplantation at the age of 1 year and was followed up until December 2022. The child had delayed language and motor development. Conclusions UCDs in newborns have a high mortality rate and a poor prognosis, and the clinical features are often unspecific. Early blood ammonia detection is the key to detect the disease, and genetic analysis can confirm the diagnosis. Early and effective intervention can save the children’s life and improve their neurological prognosis.

    General Report
    Clinical and electroencephalographic characteristics of CDKL5 gene-related early onset epileptic encepha-lopathy
    LI Heting, LUO Xiaoqing, JIANG Jun
    Journal of Clinical Pediatrics. 2023, 41(4):  272-277.  doi:10.12372/jcp.2023.22e0953
    Abstract ( 254 )   HTML ( 20 )   PDF (2492KB) ( 192 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the clinical and electroencephalographic (EEG) features of CDKL5 gene-related early onset epileptic encephalopathy. Methods A total of 6 children diagnosed with early-onset epileptic encephalopathy from March 2013 to September 2021 and screened with CDKL5 gene variation by next-generation gene sequencing were collected. Their clinical data and EEG characteristics were analyzed retrospectively. Results The median onset age of six children was 2 months (45days-1 years), and the follow-up time was more than 1 year. All children initially had focal seizures that successively progressed to spasms, myoclonic seizures, tonic seizures, and atypical absence seizures over a period of days to 4.3 years. All the children had serious psychomotor and intellectual retardation or regression. The EEG of the children also evolved from the initial normal or focal or multifocal discharge into a highly irregular pattern, and the EEG showed a pseudo-periodic feature after 2 years of age. Among them, the EEG of one male child showed a highly irregular pattern in the early stage, and the dynamic evolution was not obvious in the course of the disease. All the CDKL5 gene variants in the 6 children were de novo variants, including insertion variants, missense variants and deletion variants. Several antiepileptic treatments failed to control seizures effectively. Adrenocorticotropic hormone (ACTH) and ketogenic diet were used in 3 patients, and growth and development were improved in 2 patients. Conclusions CDKL5-related early onset epileptic encephalopathy has early onset and mostly begins with focal seizures, and a variety of seizure types occur successively. The clinical and EEG abnormalities are more serious in boys, and the EEG of 5 girls shows a certain pattern of evolution. Different gene variation sites may have different early EEG manifestations. Epileptic seizures are not easy to control. The growth and development of some patients can be improved by administration of ACTH and ketogenic diet.

    Clinical and genetic analysis of children with 3-hydroxy-3-methyglutaryl-coenzyme A lyase deficiency
    CHANG Guoying, LING Shiying, QIU Wenjuan, ZHANG Huiwen, LIANG Lili, GU Xuefan, HAN Lianshu
    Journal of Clinical Pediatrics. 2023, 41(4):  278-283.  doi:10.12372/jcp.2023.22e0624
    Abstract ( 329 )   HTML ( 26 )   PDF (1431KB) ( 187 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To analyze the clinical characteristics and gene variation for children with 3-hydroxy-3-methyglutaryl-coenzyme A lyase deficiency (HMGCLD). Methods The clinical data and genetic sequencing results of children with HMGCLD were analyzed. Results There were 6 patients (3 boys and 3 girls). One patient had a positive family history. Neonatal screening in the local hospital indicated HMGCLD in 3 patients, 2 patients were clinically diagnosed after the onset of the disease, and 1 patient remained disease-free. The onset age of 5 patients ranged from 10 days to 5 years and the age of first diagnosis ranged from 1 month to 7 years. There were metabolic crisis, hypoglycemia and hyperlactatemia in different degrees at the onset of the disease. Two patients died. Blood tandem mass spectrometry showed an increase in 3-hydroxyisovaleryl carnitine (C5-OH), and some of the children were accompanied by an increase in hexanedioyl carnitine (C6DC). Urine organic acid analysis showed that 3-hydroxy-3-methylglutaric acid increased significantly, along with 3-methylpentene acid and 3-hydroxyisovaleric acid. The HMGCL gene variation was found in 4 patients. Two patients had a homozygous variation of c.122G>A (p.R41Q), 1 patient had a homozygous variation of c.697C>T (p.H233Y) and 1 patient had a complex heterozygous variation of c.145-2A>G and c.590G>A (p.C197Y). Among them, c.697C>T (p.H233Y), c.145-2A>G, and c.590G>A (p.C197Y) were all reported for the first time. Protein structure was predicted to be potentially harmful, and the grade of ACMG was likely pathogenic. The other two children did not undergo genetic testing. Conclusions The clinical phenotype of HMGCLD is diverse, which can be confirmed by combining blood tandem mass spectrometry, urine organic acid analysis and gene diagnosis. Screening of HMGCLD is helpful for early diagnosis and reasonable treatment.

    Study on drug resistance of six carbapenem-resistant Enterobacter xiangfangensis strains carrying blaIMP-4 gene
    SUN Jinbo, YAO Bei, HAN Tongyan, TONG Xiaomei, LI Zailing
    Journal of Clinical Pediatrics. 2023, 41(4):  284-288.  doi:10.12372/jcp.2023.21e1617
    Abstract ( 140 )   HTML ( 17 )   PDF (1203KB) ( 184 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To explore the drug resistance characteristics of Enterobacter xiangfangensis (E. xiangfangensis) infection in neonatal intensive care unit. Methods Six strains of E. xiangfangensis were isolated from newborns in neonatal intensive care unit from December 2019 to February 2020. These strains were tested for drug resistance using both broth dilution method and disc diffusion method, and 150bp multiple insert size paired-end sequencing was performed using the Illuminanovaseq 6000 to detect drug resistant genes. Meanwhile, clinical data of the children infected with the drug-resistant strains were collected. Results Six strains of E. xiangfangensis were derived from 5 premature infants. One of them was positive in sputum culture, which was considered as colonization. The other 4 infants were sepsis, and 4 cases of sepsis had high risk factors for infection. A premature infant experienced E. xiangfangensis septicemia twice during hospitalization. Drug susceptibility test showed that 6 strains of E. xiangfangensis were sensitive to tigacycline, amikacin and cotrimoxazole. Sensitivity to ciprofloxacin was observed in 1 strain, sensitivity to piperacillin tazobactam was observed in 5 strains, sensitivity to cefoperazone sodium sulbactam was observed in 4 strains, and sensitivity to minocycline was observed in 2 strains. All strains were resistant or intermediate to carbapenems such as meropenem. Identification of the drug resistant genes showed that β-lactam resistance genes blaIMP-4 or laACT-55 and quinolone resistance gene qnrS1 were identified in all 6 strains, aminoglycoside resistance gene aac(6')-Ib4 was found in 5 strains, quinolone resistance gene qnrS1 and sulfonamide resistance gene sul1 coexisted in 5 strains, quinolone resistance genes oqxA9 or oqxB9 also coexisted in 5 strains. Multilocus sequence typing showed that all the 6 strains of E. xiangfangensis had the same sequence type of 148. Conclusions E. xiangfangensis resistance to carbapenems may not be caused by the expression of carbapenem-resistant genes. Antibiotics should be selected reasonably according to the characteristics of bacterial resistance to reduce the generations of resistant bacteria, rather than blindly selecting the carbapenem antibiotics.

    Pulmonary vein stenosis in extremely premature infants with bronchopulmonary dysplasia: a report of two cases
    WANG Liping, YOU You, YIN Zhanghua, WANG Yiwen, CHEN Sun, XIA Hongping
    Journal of Clinical Pediatrics. 2023, 41(4):  289-293.  doi:10.12372/jcp.2023.22e0665
    Abstract ( 192 )   HTML ( 32 )   PDF (1602KB) ( 219 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the clinical characteristics and treatment of pulmonary vein stenosis (PVS) in extremely premature infants with bronchopulmonary dysplasia. Methods The clinical characteristics of PVS in two extremely premature infants with bronchopulmonary dysplasia were retrospectively analyzed and the related literatures were reviewed. Results The two infants were both small for gestational age and the gestational age was 30+1 weeks and 28+2 weeks, respectively. They were diagnosed with bronchopulmonary dysplasia with pulmonary hypertension. Case 1 had left PVS at 4 months and 20 days after birth, and he died after ineffective drug treatment. Case 2 had left PVS at 3 months after birth, and right upper PVS was found at 5 months and 15 days after birth. She received pulmonary vein balloon dilation therapy and pulmonary hypertension improved. More than a month after discharge, PVS relapsed and she received PVS correction operation. However, pulmonary vein turned stenosis again, the parents gave up further treatment and she died later. Conclusions Echocardiography should be performed in extremely premature infants with bronchopulmonary dysplasia and pulmonary hypertension, and pulmonary vein need to be evaluated carefully. When vasodilator drug treatment is ineffective, intervention or surgical operation could be considered. However, the overall mortality rate is high.

    Therapeutic efficacy of an SGLT2 inhibitor in five pediatric patients with glycogen storage disease type Ⅰb and inflammatory bowel disease
    XIA Yu, GE Wensong, DU Taozi, GONG Zizhen, XIAO Bing, LIANG Lili, WANG Ruifang, YANG Yi, QIU Wenjuan
    Journal of Clinical Pediatrics. 2023, 41(4):  294-299.  doi:10.12372/jcp.2023.22e0095
    Abstract ( 192 )   HTML ( 21 )   PDF (1231KB) ( 156 )  
    Figures and Tables | References | Related Articles | Metrics

    Objective To analyze the therapeutic effect of a sodium-glucose co-transporter 2 (SGLT2) inhibitor in five pediatric patients with glycogen storage disease type Ⅰb (GSD-Ⅰb) and inflammatory bowel disease (IBD). Methods Changes in clinical manifestations and laboratory tests of five pediatric GSD-Ⅰb patients with IBD before and after the administration of a SGLT2 inhibitor from 2021 to 2022 were analyzed retrospectively. Results The median age of IBD onset was 5.0 years old. All five patients presented with oral ulcers, abdominal pain, diarrhea and perianal abscess. Before the administration of the SGLT2 inhibitor, the median pediatric Crohn’s disease activity index (PCDAI) was 55.0. After the treatment [median length of treatment: 12.0 months, median dose at the last follow-up: 0.31 mg/(kg·d)], the median PCDAI (10.0) was significantly decreased (P=0.043), and all the patients achieved clinical response. During the treatment, 2 patients developed hypoglycemia and 4 patients developed pruritus in perineum or urethral orifice. Two novel SLC37A4 variants were identified (c.2delT, c.1065delG) and c.446G>A (p.G149E) was a hotspot variant (70%). Conclusions The SGLT2 inhibitor can significantly and safely reduce the disease activity of IBD in pediatric GSD-Ⅰb patients.

    Literature Review
    Research advances of the diagnosis and management for mucormycosis following hematopoietic stem cell transplant in children
    XI Bixin, HU Qun, ZHAO Xin, LIU Aiguo
    Journal of Clinical Pediatrics. 2023, 41(4):  311-315.  doi:10.12372/jcp.2023.22e0025
    Abstract ( 229 )   HTML ( 27 )   PDF (1147KB) ( 185 )  
    Figures and Tables | References | Related Articles | Metrics

    The pediatric mucormycosis is a rare but often highly lethal complication after hematopoietic stem cell transplantation (HSCT). Of the hazard factors, immunosuppression post HSCT, neutropenia, graft-versus-host disease (GVHD), Iron overload, parenteral hyperalimentation, and the use of corticosteroid or calcineurin inhibitors, particularly in children, have been reported to be the commonest contributions to mucormycosis. An early diagnosis and combined treatment of mucormycosis is challenging due to the nature of often rapidly invasion and destruction. This article reviews the research advances in epidemiological characteristics, pathogenesis, diagnosis and treatment of mucormycosis in children after HSCT, and provides suggestions for further improvement of the diagnosis and treatment of mucormycosis in children after transplantation.

    Continuing Medical Education
    Research progress of renal oxygen saturation in the diagnosis of acute kidney injury ZHANG Jinming, WANG Lijie
    ZHANG Jinming, WANG Lijie
    Journal of Clinical Pediatrics. 2023, 41(4):  316-320.  doi:10.12372/jcp.2023.22e0286
    Abstract ( 229 )   HTML ( 22 )   PDF (1156KB) ( 135 )  
    References | Related Articles | Metrics

    Under the action of various etiologies such as fluid loss, infection and immune diseases, the renal tissue is prone to hypoxia and ischemia, resulting in acute kidney injury (AKI) due to its relatively weak autonomic regulation ability. The incidence of AKI is high, which seriously affects the prognosis of critically ill children, but there is a lack of clinically applicable early diagnosis indicators. In recent years, the application of near infrared reflectance spectroscopy (NIRS) to monitor renal oxygen saturation (RrSO2) can reflect renal blood perfusion and indirectly reflect renal function. Based on the research progress of RrSO2 at home and abroad, this paper summarized the clinical application of NIRS in kidney, and proposed that RrSO2 could be used as a powerful indicator for clinical diagnosis of AKI.